Table 3: Results of clinical trials of H5–LAIVs against potentially pandemic influenza viruses in healthy vaccinated adults after the first and the second doses.
| H5–LAIV |
Dose |
Number (%) of Positive Subjects of Total Number Vaccinees |
Refs. |
| Adverse Reactions |
Virus Shedding |
Genetic Stability |
Immunogenicity2
|
| Local1
|
Systemic2
|
PCR3
|
Culture4
|
Stability of att Mutations |
Any Antibody Response5
|
Any Cell Mediated Response6
|
| Len–dP |
1 |
8/20 (40) |
0/20 (0) |
Not tested |
11/20 (55) |
Confirmed |
16/42 (38) |
4/10 (40) |
[39, 48] |
| 2 |
0/20 (0) |
0/20 (0) |
14/20 (70) |
30/42 (71) |
6/10 (60) |
| Len–tT |
1 |
2/30 (7) |
12/30 (40) |
28/30 (93) |
10/30 (33) |
Confirmed |
8/29 (28) |
13/29 (45) |
[40, 42] |
| 2 |
1/29 (3) |
6/29 (20) |
21/29 (72) |
6/29 (21) |
23/29 (79) |
12/29 (41) |
1Local adverse reactions (nasal congestion, sneezing, runny nose, hyperemia of the fauces and arches, catarrhal nasopharynx).
2Systemic adverse reactions (fever, chills, fatigue, sore throat, headache, muscle and joint aches, nausea, vomiting, cough).
3Detection of vaccine virus in nasal wash/swab samples by RT–PCR.
4Isolation of vaccine virus from nasal wash/swab samples in embryonated chicken eggs.
5Antibody immune responses (serum IgG, serum IgA, mucosal IgA).
6Cell mediated immune responses (virus–specific CD4+IFNγ+ and CD8+IFNγ+).